Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission-Reference-Cited by-同舟云学术

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Published:2013-09-05 Issue:10 Volume:122 Page:1813-1821
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Walter Roland B.¹²³,Buckley Sarah A.⁴,Pagel John M.¹⁵,Wood Brent L.⁶,Storer Barry E.¹,Sandmaier Brenda M.¹⁵,Fang Min¹,Gyurkocza Boglarka¹⁵,Delaney Colleen¹⁷,Radich Jerald P.¹⁵,Estey Elihu H.¹²,Appelbaum Frederick R.¹⁵

Affiliation:

1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and

2. Department of Medicine, Division of Hematology,

3. Department of Epidemiology,

4. Department of Medicine, Residency Program,

5. Department of Medicine, Division of Medical Oncology,

6. Department of Laboratory Medicine, Division of Hematopathology, and

7. Department of Pediatrics, University of Washington, Seattle, WA

Abstract

Key Points The negative impact of pre-HCT flow cytometrically determined MRD is similar for AML in CR1 and CR2. Even minute levels of MRD (≤0.1%) are associated with adverse outcome.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/10/1813/1368222/1813.pdf

Reference21 articles.

1. Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia.;Hamilton;Stem Cells,2012

2. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.;Cornelissen;Nat Rev Clin Oncol,2012

3. Minimal residual disease in leukaemia patients.;Szczepański;Lancet Oncol,2001

4. Monitoring of minimal residual disease in acute myeloid leukemia.;Kern;Cancer,2008

5. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.;Buccisano;Blood,2012

Cited by 308 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study;Annals of Hematology;2024-09-07

2. Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Adult Acute Myeloid Leukemia: Outcomes and Prognostic Factors;Transplantation and Cellular Therapy;2024-09

3. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

4. Novel insights and therapeutic approaches in secondary AML;Frontiers in Oncology;2024-07-29

5. Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms;Transplantation and Cellular Therapy;2024-07